CCG
VRTX icon

Cypress Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Cypress Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,278
Closed -$594K – 310
2024
Q3 		$594K Sell
1,278
-87
-6% -$41.8K 0.07% 208
2024
Q2 		$640K Sell
1,365
-740
-35% -$321K 0.08% 185
2024
Q1 		$880K Sell
2,105
-329
-14% -$139K 0.11% 164
2023
Q4 		$990K Sell
2,434
-243
-9% -$89.8K 0.13% 141
2023
Q3 		$931K Sell
2,677
-36
-1% -$12.6K 0.13% 140
2023
Q2 		$955K Buy
2,713
+821
+43% +$277K 0.14% 145
2023
Q1 		$596K Sell
1,892
-58
-3% -$17.4K 0.09% 198
2022
Q4 		$563K Buy
1,950
+649
+50% +$198K 0.09% 202
2022
Q3 		$377K Buy
1,301
+510
+64% +$147K 0.06% 210
2022
Q2 		$223K Hold
791
– – 0.03% 268
2022
Q1 		$207K Sell
791
-882
-53% -$209K 0.03% 296
2021
Q4 		$367K Sell
1,673
-1,663
-50% -$323K 0.05% 237
2021
Q3 		$605K Sell
3,336
-322
-9% -$62.9K 0.08% 194
2021
Q2 		$738K Sell
3,658
-649
-15% -$136K 0.1% 183
2021
Q1 		$926K Sell
4,307
-1,364
-24% -$300K 0.13% 150
2020
Q4 		$1.34M Sell
5,671
-1,761
-24% -$404K 0.2% 111
2020
Q3 		$2.02M Buy
7,432
+1,907
+35% +$526K 0.34% 76
2020
Q2 		$1.6M Buy
5,525
+4,567
+477% +$1.24M 0.29% 85
2020
Q1 		$228K Hold
958
– – 0.05% 185
2019
Q4 		$210K Buy
+958
New +$194K 0.04% 230

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cypress Capital Group's VRTX Position: Q4 2024 in Review

Cypress Capital Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 1,278 shares — an estimated $594K sold.

Cypress Capital Group first reported a position in VRTX in Q4 2019 and held it in 20 quarters. The position peaked at $2.02M in Q3 2020. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Cypress Capital Group reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cypress Capital Group sold 1,278 Vertex Pharmaceuticals shares in Q4 2024, an estimated $594K.
  • Cypress Capital Group first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 20 quarters.
  • Cypress Capital Group's Vertex Pharmaceuticals position peaked at $2.02M in Q3 2020.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Cypress Capital Group's 13F filing for Q4 2024, filed 6 Feb 2025.